Investment advice
Industry strategy: in 2021, the total scale of investment and financing in the field of medicine and health was relatively stable, the number of investment and financing events increased significantly, and the investment and financing heat in the field of medical treatment remained unchanged. Investment and financing data can predict the performance of the secondary market, so we will continue to be optimistic about the field of medicine and health in 2022. We recommend paying attention to areas with high investment and financing in the field of medicine and health, including innovative drugs, CXO and biological products. At the same time, we can continue to pay attention to the industries with obvious growth of investment and financing data in 2021, including medical devices, AI medical, medical insurance, medical consumables, organs and medical informatization.
Industry perspective
The investment and financing amount data has certain guiding significance for the secondary market: comparing the investment and financing amount in the field of China Meheco Group Co.Ltd(600056) with the stock price trend of the pharmaceutical sector from 2017 to the end of 2021, it can be seen that the stock price trend lags behind the investment and financing amount trend as a whole, and the stock price often increases with the increase of investment and financing amount after one quarter. Therefore, pay attention to the change of investment and financing amount in the medical field, It can play a certain prediction effect for the secondary market.
The scale of investment and financing in the medical field in 2021 remains unchanged: as of January 31, 2022, the total investment and financing in the global medical field in 2021 reached US $108.1 billion, a slight decrease compared with us $110.4 billion in 2020; In 2021, there were about 1745 investment and financing events in the global medical field, an increase of 6.5% compared with 1638 events in 2020. Overall, the scale of investment and financing in the medical field in 2021 is similar to that in 2020, but the marginal growth effect is weakened.
China’s investment and financing data are generally stable, while overseas investment and financing are generally weak: for China, the total investment and financing in the medical field reached US $32.2 billion in 2021, a decrease of about 6.0% compared with us $34.2 billion in 2020; There were about 689 investment and financing events in China’s medical field, an increase of 28.3% compared with 537 events in 2020. Overseas, the total scale of investment and financing reached US $76 billion and US $76.2 billion in 2021 and 2020, respectively. The total scale was stable, and the number of investment and financing events reached 1056 and 1101 respectively, a slight decrease.
The number of global early-stage investment has increased significantly, and the number of strategic investment events in China is significantly higher than overseas: from the perspective of global investment and financing rounds, the number of global early-stage investment (including seed round, angel round, pre-A round and a-round investment), IPO and other events has increased significantly; The number of overseas strategic investment decreased significantly, by about 46.9% in 2021; The number of strategic investment events in China is on the rise, rising by 30.1% in 2021.
The investment in innovative drugs still occupies the leading position, and the growth of medical devices and other industries is obvious: innovative drugs accounted for 31.7% of the overall investment and financing scale in 2021, and still occupied the leading position; The industry sectors maintaining positive growth in 2021 include medical devices, medical services, in vitro diagnosis, CXO, AI medical treatment, medical insurance, API, medical consumables, medical equipment, organs, medical informatization, etc., among which the growth of medical devices, AI medical treatment, medical insurance, medical consumables, organs and medical informatization is more obvious.
Risk tips
Omission of events, deviation of sub industry division, exchange rate error, etc.
